Marijuana Use in Adults Living with Sickle Cell Disease
Most States Do Not Specify Sickle Cell Disease as a Qualifying Condition for Legal Access to Marijuana
GEN Roundup: Multiplexed Immunoassays: Small Samples, Big Pictures
Taking in "Everything All at Once" Can Reveal Meaningful Biological Patterns and Drug Targets
Scaling Up Cell Therapy Manufacturing
Moving Forward with an Early-on Strategy
10 Takeover Targets to Watch This Fall
Pace of Biopharma M&A Slows from First Half Stampede of Deals
For full access to this article login to GEN Select now.
Finding New Formats for Good Old Protein A
Protein A Is Adapting To New Manufacturing Challenges and Becoming More Competitive All the Time
- Protein A continues to be the method of choice for the purification of monoclonal antibodies (mAb), a sector of the biopharmaceutical industry that has grown substantially since the first FDA-approved therapy in 1986. On average, four new mAb products are commercialized each year, and three new therapies have already received ...
Not registered yet? Please fill out the form below and enjoy complimentary access to this and an exclusive collection of premium content and personalization features as a GEN Select insider. Learn More.
Get GEN Select Access Now
- Do not put any letters or characters here if you are not a spy program.